• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Bonanni Luciano B bought $66,110 worth of FONAR CORPORATION COMMON STOCK (4,700 units at $14.07), increasing direct ownership by 9% to 54,253 units

    10/3/22 6:41:44 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $FONR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Bonanni Luciano B

    (Last) (First) (Middle)
    110 MARCUS DR.

    (Street)
    MELVILLE NY 11747

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    FONAR CORP [ FONR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Exec VP, COO & PFO
    3. Date of Earliest Transaction (Month/Day/Year)
    09/29/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    FONAR CORPORATION COMMON STOCK 09/29/2022 P 1,300 A $13.82 50,853 D
    FONAR CORPORATION COMMON STOCK 09/30/2022 P 3,400 A $14.16 54,253 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    LUCIANO B BONANNI 10/03/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $FONR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FONR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FONR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fonar Announces Fiscal 2025 Financial Results for 3rd Quarter and Nine-Month Period

      Net Income increased 25% to $3.1 million for the quarter ended March 31, 2025 as compared to the quarter ended March 31, 2024. Income from Operations for the quarter ended March 31, 2025 decreased 2% to $3.7 million as compared to the quarter ended March 31, 2024. Diluted Net Income Per Common Share Available to Common Stockholders increased 37% to $0.37 per share for the quarter ended March 31, 2025 as compared to the quarter ended March 31, 2024.Total Revenues-Net increased 6% to $27.2 million for the quarter ended March 31, 2025 as compared to the quarter ended March 31, 2024. Total Cash, Cash Equivalents and Short-Term Investments decreased 4% to $54.4 million at March 31, 2025 as compar

      5/15/25 7:00:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Announces Six Month and 2nd Quarter Financial Results for Fiscal 2025

      MRI scan volume at HMCA managed sites increased 7% to 79,207 scans during the six-month period ended December 31, 2024, versus 73,776 scans for the six-month period ended December 31, 2023. MRI scan volume at HMCA owned sites decreased 4% to 26,961 scans during the six-month period ended December 31, 2024, versus 28,214 scans for the six-month period ended December 31, 2023.Cash and Cash Equivalents and Short-term Iinvestments decreased 5% to $53.7 million at December 31, 2024, versus the fiscal year ended June 30, 2024. Total Revenues-Net for the six-month period ended December 31, 2024, decreased by 3% to $49.9 million, and for the quarter ended December 31, 2024, decreased by 2% to $25.0

      2/18/25 7:37:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Announces Financial Results for the 1st Quarter of Fiscal 2025

      Total MRI scan volume at the HMCA-managed sites increased 5% to 53,054 scans for the quarter ending September 30, 2024 versus the corresponding quarter one year earlier. Cash and cash equivalents decreased 4% to $54.2 million at September 30, 2024 as compared to the fiscal year-ended June 30, 2024.Total Revenues - Net decreased by 3% to $25.0 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.Income from Operations decreased 30% to $4.6 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.Net Income decreased 25% to $4.0 million for the quarter ended September 30, 2024 versus the corresponding quart

      11/12/24 7:00:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Fonar Corporation

      SC 13G - FONAR CORP (0000355019) (Subject)

      11/14/24 12:27:58 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Fonar Corporation

      SC 13G - FONAR CORP (0000355019) (Subject)

      2/13/24 5:04:39 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Fonar Corporation (Amendment)

      SC 13G/A - FONAR CORP (0000355019) (Subject)

      2/13/24 4:05:17 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    Leadership Updates

    Live Leadership Updates

    See more
    • FONAR Board of Directors Appoints Independent Director

      Melville, New York--(Newsfile Corp. - March 20, 2023) - FONAR Corporation (NASDAQ:FONR), The Inventor of MR Scanning, today announced that its board of directors appointed Jessica Maher as a replacement independent director to a vacancy on the Company's board of directors and audit committee.Timothy Damadian, chairman, president and CEO of FONAR, said, "FONAR's primary source of income and growth is attributable to its diagnostic imaging management subsidiary, Health Management Company of America (HMCA). As a management company, HMCA bills and collects for all services rendered at HMCA-managed and HMCA-owned facilities. These facilities, all of them located in New York and Florida and coll

      3/20/23 11:37:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Board of Directors Appoints Independent Director

      Melville, New York--(Newsfile Corp. - November 23, 2021) - FONAR Corporation (NASDAQ:FONR), The Inventor of MR Scanning, today announced that on November 17, 2021, its board of directors appointed John Collins as a replacement independent director to a vacancy on the Company's board of directors and audit committee.Timothy Damadian, president and CEO of FONAR, said, "Our primary source of income and growth is attributable to FONAR's diagnostic imaging management subsidiary, Health Management Company of America (HMCA). Mr. Collins' extensive experience in dealing with insurance companies will be very helpful to HMCA. As a management company, HMCA bills and collects for all services rendered

      11/23/21 2:07:00 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Fonar Corporation

      10-Q - FONAR CORP (0000355019) (Filer)

      5/15/25 2:14:54 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEF 14A filed by Fonar Corporation

      DEF 14A - FONAR CORP (0000355019) (Filer)

      4/7/25 3:03:53 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Corporation filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - FONAR CORP (0000355019) (Filer)

      2/19/25 4:16:47 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Bonanni Luciano B bought $66,110 worth of FONAR CORPORATION COMMON STOCK (4,700 units at $14.07), increasing direct ownership by 9% to 54,253 units

      4 - FONAR CORP (0000355019) (Issuer)

      10/3/22 6:41:44 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4: Damadian Timothy Raymond bought $65,205 worth of FONAR CORPORATION COMMON STOCK (4,700 units at $13.87), increasing direct ownership by 12% to 42,700 units

      4 - FONAR CORP (0000355019) (Issuer)

      10/3/22 6:16:39 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    Financials

    Live finance-specific insights

    See more
    • Fonar Announces Financial Results for the 1st Quarter of Fiscal 2025

      Total MRI scan volume at the HMCA-managed sites increased 5% to 53,054 scans for the quarter ending September 30, 2024 versus the corresponding quarter one year earlier. Cash and cash equivalents decreased 4% to $54.2 million at September 30, 2024 as compared to the fiscal year-ended June 30, 2024.Total Revenues - Net decreased by 3% to $25.0 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.Income from Operations decreased 30% to $4.6 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.Net Income decreased 25% to $4.0 million for the quarter ended September 30, 2024 versus the corresponding quart

      11/12/24 7:00:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Announces Financial Results for Fiscal 2023 3rd Quarter and Nine-Month Period

      Total MRI scan volume at the HMCA-managed sites increased 7% to 49,451 scans for the quarter ended March 31, 2023 versus the corresponding quarter one year earlier. For the nine-month period ended March 31, 2023, 139,339 scans were performed as compared to 140,650 for the corresponding nine-month period one year ago.Net Income increased 37% to $4.5 million for the quarter ended March 31, 2023 and decreased 27% to $9.9 million for the nine-month period ended March 31, 2023. Diluted Net Income Per Common Share Available to Common Stockholders increased 72% to $0.55 for the third fiscal quarter ended March 31, 2023 and decreased 19% to $1.16 for the nine-month period ended March 31, 2023. Tota

      5/15/23 4:05:00 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Announces Financial Results for Fiscal 2021 as Diluted EPS Increases 23%

      Total MRI scan volume at the HMCA-managed sites increased 7 % to 178,364 scans for the fiscal year ending June 30, 2021 as compared to the prior year.Total Revenues-Net increased by 5% to $89.9 million for the fiscal year ended June 30, 2021, versus the previous fiscal year.Income from Operations increased 25% to $17.1 million for the fiscal year ended June 30, 2021, versus the previous fiscal year.Net Income increased 17% to $13.7 million for the fiscal year ended June 30, 2021 versus the previous fiscal year.Diluted Net Income per Common Share increased 23% to $1.45 for the fiscal year ended June 30, 2021 versus the previous fiscal year. Book Value Per Share increased by 6% to $20.41 per s

      9/28/21 7:30:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care